

The Congressionally Directed Medical Research Programs

Peer Reviewed Medical Research Program (PRMRP)

Presented by

Kathryn Argue, Ph.D.

Deputy Program Manager

Webinar presented to the National Fragile X Foundation

10 April 2024



Transforming Healthcare through Innovative and Impactful Research



CDMRP
DEPARTMENT OF DEFENSE
CONGRESSIONALLY DIRECTED
MEDICAL RESEARCH PROGRAMS

The views expressed in this presentation are those of the author and may not reflect the official policy or position of the Department of the Army, Department of Defense, or the U.S. government. Future use of this presentation does not constitute, express, or imply endorsement of the user by the Department of the Army.

UNCLASSIFIED

For more information, visit cdmrp.health.mil

- Overview of CDMRP
- Program Cycle and Review Process
- Peer Reviewed Medical Research Program (PRMRP)
- Funding Opportunities and Application Process
- Resources for a Successful Application



Vision

Transforming healthcare through innovative and impactful research

Mission

Responsibly manage collaborative research that discovers, develops, and delivers health care solutions for Service Members, their Families, Veterans and the American public





<https://cdmrp.health.mil>

STEWARDSHIP



- **Manages targeted research funds** added by Congress to the DOD budget
- **Obligates funds up-front**; limited out-year budget commitments
- **Maximizes funding available for research** through low management costs and efficient processes
- **Maintains transparency and accountability**

COLLABORATION



- **Integrates consumers as full participants** throughout program processes and as the “True North” of CDMRP
- **Collaborates with other funding organizations** – complimentary, not duplicative

STRATEGY



- **Annually adapts each program's vision and investment strategy**, allowing rapid response to changing needs, opportunities, and congressional intent
- **Publicly announces and competes funding opportunities**
- Ensures scientific excellence and programmatic relevance through the National Academy of Medicine-recommended **two-tiered review process**

IMPACT



- Targets research that **fills gaps and addresses high-priority needs**
- **Funds impactful, innovative research for specific programs added by Congress to the Defense Appropriations Bill**
- **Focused on improving health, well-being, and health care quality for those affected**

CDMRP FY24 Appropriations



Research Program	FY24 \$M	Research Program	FY24 \$M
Alcohol and Substance Use Disorders	\$4.0	Neurofibromatosis	\$25.0
Amiotrophic Lateral Sclerosis	\$40.0	Ovarian Cancer	\$45.0
Arthritis <i>(New for FY24)</i>	\$10.0	Pancreatic Cancer	\$15.0
Autism	\$15.0	Parkinson's	\$16.0
Bone Marrow Failure	\$7.5	Peer Reviewed Alzheimer's	\$15.0
Breast Cancer	\$150.0	Peer Reviewed Cancer (18 Topics)	\$130.0
Combat Readiness Medical	\$5.0	Peer Reviewed Medical (42 Topics)	\$370.0
Duchenne Muscular Dystrophy	\$10.0	Peer Reviewed Orthopaedic	\$30.0
Epilepsy	\$12.0	Prostate Cancer	\$110.0
Hearing Restoration	\$5.0	Rare Cancers	\$17.5
Glioblastoma <i>(New for FY24)</i>	\$10.0	Reconstructive Transplant	\$12.0
Joint Warfighter Medical	\$20.0	Spinal Cord Injury	\$40.0
Kidney Cancer	\$50.0	Tick-Borne Disease	\$7.0
Lung Cancer	\$25.0	Toxic Exposures	\$30.0
Lupus	\$10.0	Traumatic Brain Injury and Psychological Health	\$175.0
Melanoma	\$40.0	Tuberous Sclerosis Complex	\$8.0
Military Burn	\$10.0	Vision	\$20.0
Multiple Sclerosis	\$20.0		
		TOTAL = \$1.51B	

- Every program aligns with CDMRP's overarching vision of transforming healthcare for Service Members (SMs), Veterans and the American public

Select examples of incidence in the military:

- Post-traumatic epilepsy affects >2,000 Iraq/Afghanistan War Veterans, with 5x higher mortality rate
- Female active duty SMs have a higher incidence rate of breast cancer
- SMs are at a 50% greater risk for ALS
- Substance abuse responsible for ~30% of Army's suicide deaths
- Deployment associated with 1.8-fold increased risk of Parkinson's
- Risk of dementia is 2-4x higher in SMs; increases by 70% following a TBI




- Commitment to the health and wellbeing of DOD families also directly contributes to the readiness of Service Members by allowing them to focus on their military mission
 - Over 15,000 military dependents have a diagnosis of autism spectrum disorder
- CDMRP-funded research generates products that provide better preventions, novel diagnostics and prognostics, improved treatments and therapies, and more effective rehabilitation and restorative strategies – **to improve lives**

CDMRP Program Cycle and Review Process



Transforming Healthcare through Innovative and Impactful Research

Program Cycle



Goal of the Two-Tier Review Process

To develop funding recommendations that balance *the most meritorious science* across many disciplines and offer the highest promise to *fulfill the programmatic goals* set forth in the funding opportunity

Peer Review

- Criterion-based evaluation of full proposal
- Determination of “absolute” scientific merit
- **Outcome: Summary Statements**
 - No standing panels; reviewers are recruited based on expertise needed
 - No contact between applicants, reviewers, and program staff

Partnership



Programmatic Review

- Comparison among proposals of high scientific merit
- Determination of adherence to intent, program relevance, and potential for impact
- **Outcome: Funding Recommendations**
 - No “pay line” (portfolio balance)
 - Funds obligated up-front; limited out-year budget commitments (but milestones imposed)
 - No continuation funding



Video and additional information available at: <https://cdmrp.health.mil/about/2tierRevProcess>


Consumers are the “True North” and Foundation of the CDMRP

CDMRP includes consumers – patients, survivors, family members, and/or caregivers – in every aspect of the program lifecycle.

Consumers serve as full voting members on peer review and programmatic panels. Through their lived experiences with the target disease, disorder, or injury, consumers represent their respective communities and add valuable perspectives and a sense of urgency to the program mission, investment strategy, and research focus.



PROGRAM LIFECYCLE



FY22 Consumer Involvement

80 consumers* were assigned to Programmatic Panels as members and ad hoc reviewers representing **65** consumer advocacy organizations, active-duty Service Members, or Veterans

855 consumer reviewers** were assigned to Peer Review Panels representing **415** consumer advocacy (nominating) organizations

Consumer advocates also participate on research teams for funded projects

* All unique individuals
** 737 unique individuals



Peer Reviewed Medical Research Program (PRMRP)


A decorative banner spans the width of the slide. It has a dark blue background. On the left side, there is a faint, glowing molecular structure. On the right side, there is a silhouette of a family (two adults and a child) standing on a dark surface, looking out at a bright, glowing blue light that resembles a DNA helix or a network of connections. The banner is partially overlaid by a large, dark blue arrow pointing to the right.

Transforming Healthcare through Innovative and Impactful Research

Vision: Improve the health, care, and well-being of all military Service Members, Veterans, and their Families

Mission: Encourage, identify, select and manage medical research projects of clear scientific merit that lead to impactful advances in health care of Service Members, Veterans, and their Families

- Initiated in 1999 to address diseases and conditions with relevance to military health
- Direction from congress to support research of “clear scientific merit” and “direct relevance to military health” in specified topic areas




<https://cdmrp.health.mil/prmrp/default>

FY24 Topic Areas (42 total) for Peer Reviewed Medical Research Program

- Accelerated Aging Processes Associated with the Military*
- Celiac Disease
- Computational Biology for Precision Health*
- Congenital Cytomegalovirus*
- Congenital Heart Disease
- Dystonia
- Eating Disorders
- Ehlers-Danlos Syndrome
- Epidermolysis Bullosa
- Far-UVC Germicidal Light*
- Fibrous Dysplasia/McCune Albright Syndrome
- Focal Segmental Glomerulosclerosis
- Food Allergies
- Fragile X
- Frontotemporal Degeneration
- Guillain-Barre Syndrome
- Hepatitis B
- Hereditary Ataxia
- Hydrocephalus
- Inflammatory Bowel Disease
- Interstitial Cystitis
- Lymphedema
- Malaria
- Maternal Mental Health
- Mitochondrial Disease
- Musculoskeletal Disorders Related to Acute and Chronic Bone Conditions and Injuries
- Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
- Myotonic Dystrophy
- Nephrotic Syndrome
- Neuroactive Steroids
- Pancreatitis
- Peripheral Neuropathy
- Polycystic Kidney Disease
- Proteomics
- Pulmonary Fibrosis
- Respiratory Health
- Rett Syndrome
- Scleroderma
- Sickle-Cell Disease
- Suicide Prevention
- Vascular Malformations
- Von Hippel-Lindau Syndrome

Applicants must address at least one of the Topic Areas, which are directed by Congress



**Assigned for the first time in FY24*

PRMRP's Portfolio-Driven Approach




Autoimmune Disorders and Immunology

- Celiac Disease
- Computational Biology for Precision Health
- Food Allergies
- Guillain-Barre Syndrome
- Inflammatory Bowel Disease
- Proteomics
- Scleroderma



Cardiovascular Health

- Computational Biology for Precision Health
- Congenital Heart Disease
- Proteomics
- Vascular Malformations



Infectious Diseases

- Computational Biology for Precision Health
- Congenital Cytomegalovirus
- Far-UVC Germicidal Light
- Hepatitis B
- Malaria
- Proteomics



Internal Medicine

- Accelerated Aging Processes Associated with Military Service
- Computational Biology for Precision Health
- Focal Segmental Glomerulosclerosis
- Interstitial Cystitis
- Lymphedema
- Nephrotic Syndrome
- Pancreatitis
- Polycystic Kidney Disease
- Proteomics



Orthopaedic Medicine

- Accelerated Aging Processes Associated with Military Service
- Computational Biology for Precision Health
- Musculoskeletal Disorders Related to Acute and Chronic Bone Conditions and Injuries
- Proteomics



Respiratory Health

- Computational Biology for Precision Health
- Proteomics
- Pulmonary Fibrosis
- Respiratory Health



Neuroscience

- Computational Biology for Precision Health
- Eating Disorders
- Maternal Mental Health
- Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
- Neuroactive Steroids
- Peripheral Neuropathy
- Proteomics
- Suicide Prevention



Rare Diseases and Conditions

- Computational Biology for Precision Health
- Dystonia
- Ehlers-Danlos Syndrome
- Epidermolysis Bullosa
- Fibrous Dysplasia/McCune-Albright Syndrome
- Fragile X
- Frontotemporal Degeneration
- Hereditary Ataxia
- Hydrocephalus
- Mitochondrial Disease
- Myotonic Dystrophy
- Proteomics
- Rett Syndrome
- Sickle-Cell Disease
- Von Hippel-Lindau Syndrome

Program Priorities Set at the Portfolio Level



Portfolio-Specific Strategic Goals:

- Devised in coordination with key stakeholders
- Aligned to the Continuum of Care

Foundational

Prevention


Diagnosis

Treatment

Epidemiology

Applications must address ONE Topic Area and ONE Strategic Goal

Anticipated Award Mechanisms



Example: Rare Diseases and Conditions Portfolio Strategic Goals

Foundational Studies

- Identify biological mechanisms underlying disease onset, disease progression, or phenotype/symptomatic heterogeneity, including studies to address sex, gender, ethnic and/or racial differences.
- Elucidate how biomarkers (including genotype) are linked to disease phenotype or subtype.
- Develop novel preclinical models that recapitulate the phenotype of human disease.

Diagnosis

- Identify and validate objective biomarkers to predict onset, response to therapy, disease complications and/or disease progression.
- Develop and validate improved diagnostic criteria and screening tools for early detection or to track disease progression.
- Determine the physiological impact related to diagnosis and/or timing of a diagnosis.

Topic Areas

- [Computational Biology for Precision Health](#)
- Dystonia
- Ehlers-Danlos Syndrome
- Epidermolysis Bullosa
- Fibrous Dysplasia/McCune-Albright Syndrome
- Fragile X
- Frontotemporal Degeneration
- Hereditary Ataxia
- Hydrocephalus
- Mitochondrial Disease
- Myotonic Dystrophy
- Proteomics
- Rett Syndrome
- Sickle-Cell Disease
- Von Hippel-Lindau Syndrome

Applications must address one Strategic Goal and one Topic Area

Example: Rare Diseases and Conditions Portfolio Strategic Goals

Treatment

- Develop and test pharmacological or nonpharmacological treatments, or improve upon existing treatments, especially those that will minimize side effects.
- Develop and test curative strategies to include tissue engineering, genetic approaches, or protein replacement.
- Develop and test interventions to improve neuropsychological outcomes and cognitive symptoms and other comorbidities as defined by those with lived experience.
- Develop and test strategies to support ongoing treatments during life transitions (i.e., pediatric to adult care).

Epidemiology

- Conduct population-based studies to identify risk (i.e., carrier status), lifestyle determinates of health or protective factors that influence onset, progression and/or outcomes.
- Conduct natural history/longitudinal studies to understand incidence, prevalence, and progression of the disease/condition and carrier and modifier gene status.
- Develop and validate research tools to collect, mine, and integrate real-world data (patient-reported data, longitudinal data, etc.) with electronic medical records to guide precision medicine approaches.
- Develop clinically relevant endpoints for clinical trials.

Applications must address one Strategic Goal and one Topic Area

Topic Areas

- [Computational Biology for Precision Health](#)
- Dystonia
- Ehlers-Danlos Syndrome
- Epidermolysis Bullosa
- Fibrous Dysplasia/McCune-Albright Syndrome
- Fragile X
- Frontotemporal Degeneration
- Hereditary Ataxia
- Hydrocephalus
- Mitochondrial Disease
- Myotonic Dystrophy
- Proteomics
- Rett Syndrome
- Sickle-Cell Disease
- Von Hippel-Lindau Syndrome

FY24 PRMRP Award Mechanisms



Basic Research

Discovery Award

Direct Cost Max: \$275K

LOI/Invite: Letter of Intent

- Novel/breakthrough exploratory research, high-risk/high-reward

Investigator-Initiated Research Award

Direct Cost Max: \$1M

LOI/Invite: Letter of Intent

- Preclinical expansion, replication and/or comparative studies to validate preliminary or published data



Translational Research

Impact Award

Direct Cost Max: \$2M/2.6M

LOI/Invite: Letter of Intent

- Mature research studies with potential near-term clinical impact for patients

Technology/Therapeutic Development Award

Direct Cost Max: \$4M

LOI/Invite: Letter of Intent

- Final steps of clinical translation (IND-/IDE- enabling studies or studies required to transition a product of prototype utility)



Clinical Trials/Clinical Research

Lifestyle and Behavioral Health Interventions Research Award

Direct Cost Max: \$3M

LOI/Invite: Letter of Intent

- Clinical trials/research focused on non-pharmacological therapies, non-invasive devices, patient outcomes, or quality of life

Clinical Trial Award

Direct Cost Max: No direct cost limit

LOI/Invite: Preproposal

Full Application Submission is by Invitation Only

- Early-phase or large-scale interventional clinical trials to measure safety, effectiveness and/or efficacy outcomes

Discovery Award

- Novel/breakthrough exploratory research, beyond incremental advances
- High-risk/high-reward
- No preliminary data

Impact Award

- Mature research studies, beyond incremental advances
- Potential near-term clinical impact for patients
- Seeks to translate preclinical findings into a clinical application
- Strong in vivo preliminary data required

Clinical Trial Award

- Research that seeks to measure safety, effectiveness, and/or efficacy outcomes of an intervention in humans
- Early-phase or large-scale interventional clinical trials



Basic Research



Translational Research



Clinical Trials/ Clinical Research

Investigator-Initiated Research Award

- Preclinical expansion, replication, and/or comparative studies to validate preliminary or published data
- Preliminary data required

Technology/Therapeutic Development Award

- Final steps of clinical translation for validated findings
- IND-/IDE-enabling studies
- Post-IND/-IDE studies required to transition a product or prototype utility
- Strong preliminary data demonstrating product or prototype utility required

Lifestyle Behavioral Health Intervention Research Award

- Clinical trials for non-pharmacological therapies or non-invasive devices
- Clinical research focused on patient outcomes and quality of life

FY24 PRMRP Funding Opportunities Available

Basic Research

Translational Research

Clinical Trials/Clinical Research

Discovery Award

Direct Cost Max:
\$275K

Pre-Application:
Letter of Intent

Novel/
breakthrough
exploratory
research, high
risk/high reward

Investigator- Initiated Research Award

Direct Cost Max:
\$1M

Pre-Application:
Letter of Intent

Preclinical
expansion,
replications and/or
comparative
studies to validate
preliminary or
published data

Impact Award

Direct Cost Max:
\$2M/\$2.6M

Pre-Application:
Letter of Intent

Mature research
studies with
potential near
term clinical
impact for patients

Technology/ Therapeutic Development Award

Direct Cost Max:
\$4M

Pre-Application:
Letter of Intent

Final steps of
clinical translation
(IND-/IDE-
enabling or studies
required to
transition a
product of
prototype utility)

Lifestyle Behavioral Health Intervention Research Award

Direct Cost Max:
\$3M

Pre-Application:
Letter of Intent

Clinical
trials/research
focused on non-
pharmacological
therapies, non-
invasive devices,
patient outcomes
or quality of life

Clinical Trial Award

Direct Cost Max:
No direct cost
limit

Pre-Application:
Preproposal

Early-phase or
large scale
interventional
clinical trials to
measure safety,
effectiveness
and/or efficacy
outcomes

Letter of Intent (LOI)

UNCLASSIFIED

I. OVERVIEW OF THE FUNDING OPPORTUNITY

Program Announcement for the Department of Defense

Defense Health Program

Congressionally Directed Medical Research Programs

Peer Reviewed Medical Research Program

Clinical Trial Award

Announcement Type: Initial

Funding Opportunity Number: HT942524PRMRPCTA

Assistance Listing Number: 12.420 Military Medical
Research and Development

SUBMISSION AND REVIEW DATES AND TIMES

- Pre-Application (Preproposal) Submission Deadline: 5:00 p.m. Eastern time (ET), May 13, 2024
- Invitation to Submit an Application: June 17, 2024
- Application Submission Deadline: 11:59 p.m. ET, August 19, 2024
- End of Application Verification Period: 5:00 p.m. ET, August 22, 2024
- Peer Review: October 2024
- Programmatic Review: December 2024

Understanding the goals of the program, intent of the award mechanism, and review criteria is critical for a successful grant application

TABLE OF CONTENTS

I. OVERVIEW OF THE FUNDING OPPORTUNITY.....	1
II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY.....	3
II.A. Program Description.....	3
II.A.1 FY24 PRMRP Research Development Pipeline	3
II.A.2. FY24 PRMRP Topic Areas and Strategic Goals.....	5
II.B. Award Information	12
II.C. Eligibility Information.....	18
II.C.1. Eligible Applicants	18
II.C.2. Cost Sharing.....	19
II.C.3. Other	19
II.D. Application and Submission Information.....	19
II.D.1. Location of Application Package	19
II.D.2. Content and Form of the Application Submission	21
II.D.3. Unique Entity Identifier (UEI) and System for Award Management (SAM)	42
II.D.4. Submission Dates and Times.....	42
II.D.5. Funding Restrictions.....	43
II.D.6. Other Submission Requirements	44
II.E. Application Review Information	44
II.E.1. Criteria	44
II.E.2. Application Review and Selection Process.....	49
II.E.3. Integrity and Performance Information.....	50

Rare Diseases and Conditions Strategic Goals and Topic Areas



RARE DISEASES AND CONDITIONS

All applications under this portfolio must be aligned to Rare Diseases and Conditions by addressing one Topic Area and one Strategic Goal listed below:

TOPIC AREAS

- Computational Biology for Precision Health
- Dystonia
- Ehlers-Danlos Syndrome
- Epidermolysis Bullosa
- Fibrous Dysplasia/McCune-Albright Syndrome
- Fragile X
- Frontotemporal Degeneration
- Hereditary Ataxia
- Hydrocephalus
- Mitochondrial Disease
- Myotonic Dystrophy
- Proteomics
- Rett Syndrome
- Sickle-Cell Disease
- Von Hippel-Lindau Syndrome

STRATEGIC GOALS

Foundational Studies

- Identify biological mechanisms underlying disease onset, disease progression, or phenotype/symptomatic heterogeneity, including studies to address sex, gender, ethnic and/or racial differences.
- Elucidate how biomarkers (including genotype) are linked to disease phenotype or subtype.
- Develop novel preclinical models that recapitulate the phenotype of human disease.

Diagnosis

- Identify and validate objective biomarkers to predict onset, response to therapy, disease complications and/or disease progression.
- Develop and validate improved diagnostic criteria and screening tools for early detection or to track disease progression.
- Determine the physiological impact related to diagnosis and/or timing of a diagnosis.

Treatment

- Develop and test pharmacological or nonpharmacological treatments, or improve upon existing treatments, especially those that will minimize side effects.
- Develop and test curative strategies to include tissue engineering, genetic approaches, or protein replacement.
- Develop and test interventions to improve neuropsychological outcomes and cognitive symptoms and other comorbidities as defined by those with lived experience.
- Develop and test strategies to support ongoing treatments during life transitions (i.e., pediatric to adult care).

Epidemiology

- Conduct population-based studies to identify risk (i.e., carrier status), lifestyle determinates of health or protective factors that influence onset, progression and/or outcomes.
- Conduct natural history/longitudinal studies to understand incidence, prevalence, and progression of the disease/condition and carrier and modifier gene status.
- Develop and validate research tools to collect, mine, and integrate real-world data (patient-reported data, longitudinal data, etc.) with electronic medical records to guide precision medicine approaches.
- Develop clinically relevant endpoints for clinical trials.

Peer Review Criteria – Listed in the Funding Opportunities

II.E.1.a. Peer Review


To determine technical merit, all applications will be individually evaluated according to the following **scored criteria**, which are listed in decreasing order of importance:

Example Peer Review Criteria	
Scored	Unscored
Research Strategy and Feasibility	Environment
Impact	Budget
Transition Plan and Regulatory Strategy	Application Presentation
Personnel	



- **Impact**

- To what extent the proposed research project impacts a critical problem or an important scientific question relevant to the PI-selected FY24 PRMRP Topic Area.
- To what extent the proposed research project impacts a critical problem or an important scientific question relevant to the PI-selected FY24 PRMRP Strategic Goal.
- To what extent the proposed research has potential for short- or long-term impact on therapeutic development and/or patient care.
- To what extent the research has the potential to generate preliminary data that can be used as a foundation for future research projects.
- To what extent the research has the potential to reduce the burden of disease in the short or long term.



Programmatic Review Criteria – Listed in the Funding Opportunities

II.E.1.b. Programmatic Review

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:


- Ratings and evaluations of the peer reviewers
- Relevance to the priorities of the Defense Health Program and FY24 PRMRP, as evidenced by the following:
 - Adherence to the intent of the award mechanism
 - Relative innovation
 - Relative impact
 - Relevance to the FY24 PRMRP Topic Areas
 - Relevance to the FY24 PRMRP Strategic Goals
 - Relevance to military health
 - Program portfolio composition



Programmatic Panels

FY24 Programmatic Panel

Previous Years' Programmatic Panels




Programmatic Panel membership lists are available on the CDMRP website

Application Submission Deadlines (PRMRP)

Award Mechanism	LOI	Pre-Proposal	Dates	Invitation to submit	Full Application Deadline
Discovery Award (DA)			06 May 2024		23 May 2024
Investigator-Initiated Research Award (IIRA)			06 May 2024		23 May 2024
Impact Award (IPA)			13 May 2024		06 June 2024
Technology/Therapeutic Development (TTDA)			13 May 2024		06 June 2024
Lifestyle and Behavioral Health Interventions (LBIRA)			13 May 2024		06 June 2024
Clinical Trial (CTA)			13 May 2024	17 June 2024	19 August 2024

Application Process Overview




BO: Business Official from applicant organization
 PI: Principal Investigator from applicant organization

eBRAP: electronic Biomedical Research Application Portal
 SAM: System of Award Management

Tips, Resources, and Strategies for Success




Understanding the *goals of the program, intent of the award mechanism, and review criteria* is critical for a successful application



- The funding opportunity announcement contains information on:
 - Program Goals
 - Focus Areas/Topics
 - Award Intent
 - Required Elements, Eligibility, and Funding
 - Review Criteria
 - Deadlines

Single most important tip:
Read the announcement carefully

- ✓ **Relevance**
 - Address program-specific goals
 - **Align** the proposed work with specific guidance from the announcement
- ✓ **Impact**
 - Propose **solutions** to important problems or gaps
 - Clearly articulate translatability – how will this work **make a difference?**
- ✓ **Innovation**
 - Provide clear rationale if proposing to test new, potentially high-risk ideas or use novel approaches
- ✓ **Feasibility**
 - Justify a technically sound plan with clear approaches for contingencies
 - Include evidence of appropriate **expertise** (collaboration, consultants, etc.)
 - Ensure the study is **appropriately powered** for the proposed research outcome
 - Demonstrate **availability** and **access** to critical resources, reagents, and/or subject populations



✓ Planning/Timelines

- Include and allow adequate time in project plan for **regulatory approvals** if required
- For multi-organizational efforts, show a clear plan for **coordination** and communication
- For DOD collaborations, understand rules and plan for differences in funding process

✓ Grantsmanship

- Explain the proposed work with **clarity** and **unburdened** by jargon
- Understand the different audiences of the peer and programmatic reviews and **communicate** effectively
- **Review** application documents carefully before submission – Enlist experienced colleagues to help
- Don't break the rules for deadlines or requirements – **be compliant**



News & Highlights

Peter Fiduccia: The Importance of Polycystic Kidney Disease

Developing an Effective Treatment Option for Pancreatitis

Testing a Group Cognitive Behavioral Therapy Intervention for Suicide Prevention in Military Service Members ([external link](#))

FY23 PRMRP Recommended for Funding List

FY23 PRMRP Recommended for Funding List

Cassandra Trimnell: Advocating for Patients


Peer Reviewed Medical



Vision – *Improve the health, care, and well-being of all military Service Members, Veterans, and their families*

The Peer Reviewed Medical Research Program (PRMRP), established in fiscal year 1999 (FY99), has supported research across the full range of science and medicine, with an underlying goal of enhancing the health, care, and well-being of military Service members, Veterans, retirees, and their family members. Program oversight is provided by a programmatic panel with joint military service and interagency representation. Congressional appropriations for the PRMRP totaled \$2.35 billion through FY19 and have supported over 1600 awards in over 155 different topic areas. Congress appropriated \$360 million for the FY20 program to solicit proposals in 44 topic areas.

Throughout history, military medical research has pioneered breakthroughs in reconstructive surgery, the use of antibiotics, intensive care, burn care, and kidney dialysis in response to war time needs, benefitting Service members and civilians alike. Medical research supported by the PRMRP to address near-term military needs including military and personal readiness, continues this tradition. The PRMRP is committed to supporting research that has the potential to profoundly impact the development and implementation of medical devices, drugs, and clinical guidance that will enhance the precision and efficacy of prevention, diagnosis, and treatment across a wide range of disciplines including autoimmune diseases and immunology, cardiovascular health, endocrine health and metabolism, environmental health, infectious diseases, internal medicine, neurological and psychological health, orthopedic and regenerative medicine, and respiratory health and injury.



» Click on Image to View Program Report




» Click on Image to View Strategic Plan




<https://cdmrp.health.mil>

<p>Congressional Appropriations</p> <p>\$3.451 billion FY99-06, FY08-22</p> <p>\$370 million FY23</p> <p>Topic Areas Offered by Year (FY99-23)</p>	<p>Funding Summary</p> <p>2,164 Awards in FY99-06, FY08-22</p> <p>Recent Applications Recommended for Funding</p>
<p>Programmatic Panels</p> <p>FY24 Programmatic Panel</p> <p>Previous Years' Programmatic Panels</p>	<p>Peer Review Participants</p> <p>FY23 Peer Review Participants (pdf)</p> <p>Previous Years' Peer Review Participants</p>

Subscribe to Email Notifications

DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS [Contact Us](#) | [Site Map](#) 



Transforming Health Care through Innovative and Impactful Research

Home | [Research Programs](#) | [Funding Opportunities](#) | [Consumers](#) | [Search Awards & Publications](#) | [About Us](#) |


2024 Pre-announcements

- Amyotrophic Lateral Sclerosis
- Autism
- Breast Cancer
- Epilepsy
- Hearing Restoration
- Joint Warfighter Medical
- Lung Cancer
- Melanoma
- NEW** Military Burn
- NEW** Multiple Sclerosis
- Ovarian Cancer
- NEW** Pancreatic Cancer
- Peer Reviewed Alzheimer's
- Peer Reviewed Orthopaedic
- Prostate Cancer
- Spinal Cord Injury
- Tick-Borne Disease
- Traumatic Brain Injury
- Psychological Health
- Tuberous Sclerosis Complex
- Vision

Latest News


- RTRP** Developing online communication training to request donation for vascularized composite allotransplantation (VCA): improving performance to match new US organ donation targets [BMC Springer Nature, February 13, 2024](#)
- BCRP** Closing in on Triple-Negative Breast Cancer [Cedars-Sinai, February 13, 2024](#)
- ARP** MU study shows blood pressure drug can reduce anxiety for people with autism [University of Missouri, February 13, 2024](#)

[More News >](#)




For Investigators

- [Open Funding Opportunities >](#)
- [eBRAP: Start Pre-application >](#)
- [How to Apply >](#)




Funded Research

- [CDMRP Impact Highlights Book >](#)
- [Search Awards & Publications >](#)
- [Funded Investigators Guide >](#)
- [Research Resources >](#)



Program News & Highlights


- [Upcoming Funding Opportunities >](#)
- [Research Highlights/News >](#)
- [Webinar Series >](#)



[Subscribe to Funding Opportunities & Program Communications](#)

[Submit Technical Reports, Award & Regulatory Documents](#)

[View Research Programs >](#)



eBRAP

Electronic Biomedical Research Application Portal

[Home](#) | [About Us](#) | [Funding Opportunities & Forms](#)

Welcome to eBRAP

Register

I am a new:

*Select from drop down

Program News and Updates

- Welcome to eBRAP. To access the user guide, please [click here](#).
- COVID-19 Updates. please click [here](#) or click [here](#) for FAQs

Email Subscriptions


- To subscribe to program specific news and updates, please [click here](#)
- To remove your email from program subscription list, please [click here](#)

Help

- [Frequently Asked Questions](#)
- [Commonly Made Mistakes](#)
- [Contact the helpdesk/webmaster](#)

Sign up for listserve through CDMRP website or in eBRAP

Funding Opportunities Webinar Series



Webinar Title
Funding Opportunities and Strategies for Success
High Risk/High Gain Funding Opportunities
Team Science Funding Opportunities
Clinical Research and Clinical Trial Funding Opportunities
Funding Opportunities for the Development of Technology and/or Resources
Funding Opportunities for Early Career Investigators
Consortium-Type Funding Opportunities



https://cdmrp.health.mil/pubs/Webinars/webinar_series

Questions?
For more information, please visit:



cdmrp.health.mil



CDMRP

DEPARTMENT OF DEFENSE

**CONGRESSIONALLY DIRECTED
MEDICAL RESEARCH PROGRAMS**